3376 related articles for article (PubMed ID: 19903734)
1. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
2. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.
Sasaki K; Doh-ura K; Wakisaka Y; Iwaki T
Acta Neuropathol; 2002 Sep; 104(3):225-30. PubMed ID: 12172907
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
Chalmers KA; Love S
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
[TBL] [Abstract][Full Text] [Related]
4. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
[TBL] [Abstract][Full Text] [Related]
5. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
6. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
[TBL] [Abstract][Full Text] [Related]
7. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
Halliday GM; Macdonald V; Henderson JM
Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
[TBL] [Abstract][Full Text] [Related]
8. Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson's disease.
Mochizuki A; Komatsuzaki Y; Shoji S
Acta Neuropathol; 2002 Nov; 104(5):534-7. PubMed ID: 12410401
[TBL] [Abstract][Full Text] [Related]
9. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
10. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
[TBL] [Abstract][Full Text] [Related]
11. Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: comparison between Gallyas-Braak and Campbell-Switzer methods.
Uchihara T; Nakamura A; Mochizuki Y; Hayashi M; Orimo S; Isozaki E; Mizutani T
Acta Neuropathol; 2005 Sep; 110(3):255-60. PubMed ID: 16003542
[TBL] [Abstract][Full Text] [Related]
12. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Bukhatwa S; Zeng BY; Rose S; Jenner P
Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
[TBL] [Abstract][Full Text] [Related]
13. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease.
Langston JW; Sastry S; Chan P; Forno LS; Bolin LM; Di Monte DA
Exp Neurol; 1998 Dec; 154(2):684-90. PubMed ID: 9878203
[TBL] [Abstract][Full Text] [Related]
14. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
15. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
Kovacs GG; Milenkovic IJ; Preusser M; Budka H
Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy.
Nishie M; Mori F; Fujiwara H; Hasegawa M; Yoshimoto M; Iwatsubo T; Takahashi H; Wakabayashi K
Acta Neuropathol; 2004 Apr; 107(4):292-8. PubMed ID: 14722716
[TBL] [Abstract][Full Text] [Related]
17. FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy.
Zhao T; Severijnen LA; van der Weiden M; Zheng PP; Oostra BA; Hukema RK; Willemsen R; Kros JM; Bonifati V
J Neuropathol Exp Neurol; 2013 Jun; 72(6):482-8. PubMed ID: 23656991
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
19. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
Fitzmaurice PS; Ang L; Guttman M; Rajput AH; Furukawa Y; Kish SJ
Mov Disord; 2003 Sep; 18(9):969-76. PubMed ID: 14502663
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
